da CancerToday Media Team | Gen 21, 2026 | ctka
ctka-0010 Pembrolizumab versus Ipilimumab in Advanced Melanoma Pembrolizumab versus Ipilimumab in Advanced Melanoma Year Pembrolizumab rispetto a Ipilimumab nel Melanoma Avanzato Journal 2015 DOI NEJM PMID 10.1056/nejmoa1503093 URL 25891173...
da CancerToday Media Team | Gen 21, 2026 | ctka
ctka-0009 Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma Year Nivolumab e Ipilimumab in Combinazione o Monoterapia nel Melanoma non Trattato Journal 2015 DOI NEJM PMID...
da CancerToday Media Team | Gen 21, 2026 | ctka
ctka-0008 Use of Chemotherapy plus a Monoclonal Antibody (Trastuzumab) against HER2-Positive Metastatic Breast Cancer Use of Chemotherapy plus a Monoclonal Antibody (Trastuzumab) against HER2-Positive Metastatic Breast Cancer Year Uso di Chemioterapia e un Anticorpo...
da CancerToday Media Team | Gen 21, 2026 | ctka
ctka-0007 Efficacy and Safety of a Specific Tyrosine Kinase Inhibitor (Imatinib) in Chronic Myeloid Leukemia Efficacy and Safety of a Specific Tyrosine Kinase Inhibitor (Imatinib) in Chronic Myeloid Leukemia Year Efficacia e Sicurezza di un Inibitore Specifico della...
da CancerToday Media Team | Gen 21, 2026 | ctka
ctka-0006 Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer Year Sicurezza, Attività e Correlati Immuni dell’Anticorpo Anti-PD-1 nel Cancro Journal 2012 DOI NEJM PMID...
da CancerToday Media Team | Gen 21, 2026 | ctka
ctka-0005 The cancer genome The cancer genome Year Il genoma del cancro Journal 2009 DOI Nature PMID 10.1038/nature07943 URL 19357677 https://www.nature.com/articles/nature07943 Category Review Article Genomics Genomic Landscape Somatic Mutations Pan-cancer General...
